Company / EPS (Diluted)
ENDONOVO THERAPEUTICS, INC. EPS (Diluted) History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.03
FY2021
5-year range
-$24.83 / -$0.03
FY2017-FY2021
Trend
+99.9%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2021 after 2 years of decline, reaching $-0.03.
Based on SEC 10-K filings.
-0.03 in FY2021.
Improved from $-17.76 to $-0.03 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, eps (diluted) increased 99.9% year-over-year.
- Peak eps (diluted) was recorded in FY2011.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | -$0.03 | +99.9% |
| FY2020 | -$24.83 | -39.8% |
| FY2019 | -$17.76 | -44300.0% |
| FY2018 | -$0.04 | +42.9% |
| FY2016 | -$0.07 | -133.3% |
| FY2015 | -$0.03 | +99.2% |
| FY2014 | -$3.96 | -19700.0% |
| FY2011 | -$0.02 | - |
As of FY2021 · SEC 10-K · Updated Jun 29, 2026